Cogent Biosciences (COGT) Cash & Current Investments (2017 - 2026)

Cogent Biosciences' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $866.4 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 252.67% year-over-year to $866.4 million; the TTM figure through Mar 2026 stood at $866.4 million (up 252.67% YoY), while the FY2025 annual figure was $900.8 million, up 213.77% from the prior year.
• Cash & Current Investments was $866.4 million for Q1 2026 at Cogent Biosciences, down from $900.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $900.8 million in Q4 2025 to a low of $141.8 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $354.0 million across 5 years, with a median of $287.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments slumped 43.62% in 2025, then jumped 252.67% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $259.3 million in 2022, then rose by 2.48% to $265.7 million in 2023, then grew by 8.04% to $287.1 million in 2024, then soared by 213.77% to $900.8 million in 2025, then dropped by 3.82% to $866.4 million in 2026.
• The last three Cash & Current Investments figures came in at $866.4 million (Q1 2026), $900.8 million (Q4 2025), and $390.9 million (Q3 2025), per Business Quant data.